CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today provided a correction to AASLD abstract 1854 published in the October 2008 supplement of the journal Hepatology. The title of the abstract is “Phase 2 Study of Telaprevir Administered q8h or q12h with Peginterferon-Alfa-2a or -Alfa-2b and Ribavirin in Treatment-Naïve Subjects with Genotype 1 Hepatitis C: Week 4 Interim Results” and the abstract is to be presented at a poster session on Tuesday, November 4 from 8:00 a.m. to 12:30 p.m. PST.
